Ogawan, Victoria S.
HRN: 18-43-08 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/02/2023
CO-AMOXICLAV 625MG (TAB)
08/02/2023
08/10/2023
PO
625mg
BID
7 Days
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: No Wrong Choice Wrong Choice
Overall appropriateness: No Wrong Choice